Newbury Pharmaceuticals AB

As of May 31, 2026, Newbury Pharmaceuticals AB carries a market capitalization of 43.17M, placing it among publicly traded companies globally. Its enterprise value stands at 28.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Newbury Pharmaceuticals AB has 30.40M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Newbury Pharmaceuticals AB maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended May 31, 2026, Newbury Pharmaceuticals AB recorded 7,000.00 in income tax expense.

As of the close on October 22, 2026, Newbury Pharmaceuticals AB's stock has declined approximately 25.54% over the past 52 weeks. The 50-day moving average sits at 2.32, while the 200-day moving average is 1.75.

These figures are as of May 31, 2026. Total book value stands at 26.27M, with working capital of 215,000.00 providing operational flexibility.